Allenic aryl sulfonamide hydroxamic acids as matrix...

Details Allenic aryl sulfonamide hydroxamic acids as matrix... Allenic aryl sulfonamide hydroxamic acids as matrix...

2007-10-16

2007-10-16

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S227500, C514S575000, C540S570000, C544S058400, C562S623000

Reexamination Certificate

active

10285940

ABSTRACT:
Compounds of the formulaare useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease and HIV.

REFERENCES:
patent: 5455258 (1995-10-01), MacPherson et al.
patent: 5506242 (1996-04-01), MacPherson et al.
patent: 5552419 (1996-09-01), MacPherson et al.
patent: 5753653 (1998-05-01), Bender et al.
patent: 5770624 (1998-06-01), Parker
patent: 5804593 (1998-09-01), Warpehoski et al.
patent: 5817822 (1998-10-01), Nantermet et al.
patent: 5929097 (1999-07-01), Levin et al.
patent: 5962481 (1999-10-01), Levin et al.
patent: 5977408 (1999-11-01), Levin et al.
patent: 6162814 (2000-12-01), Levin et al.
patent: 6162821 (2000-12-01), Levin et al.
patent: 6172057 (2001-01-01), Venkatesan et al.
patent: 6197791 (2001-03-01), Venkatesan et al.
patent: 6197795 (2001-03-01), Levin et al.
patent: 6200996 (2001-03-01), Levin et al.
patent: 6225311 (2001-05-01), Levin et al.
patent: 6277885 (2001-08-01), Levin et al.
patent: 6288086 (2001-09-01), Venkatesan
patent: 6326516 (2001-12-01), Levin et al.
patent: 6331563 (2001-12-01), Venkatesan et al.
patent: 6340691 (2002-01-01), Levin et al.
patent: 6342508 (2002-01-01), Venkatesan et al.
patent: 6358980 (2002-03-01), Levin et al.
patent: 6441023 (2002-08-01), Venkatesan et al.
patent: 6444704 (2002-09-01), Venkatesan et al.
patent: 6462073 (2002-10-01), Venkatesan et al.
patent: 6498167 (2002-12-01), Levin et al.
patent: 6534491 (2003-03-01), Levin et al.
patent: 6548524 (2003-04-01), Levin et al.
patent: 6716833 (2004-04-01), Levin et al.
patent: 6753337 (2004-06-01), Levin et al.
patent: 6762178 (2004-07-01), Levin et al.
patent: 195 42 189 (1997-05-01), None
patent: 606046 (1994-07-01), None
patent: 757037 (1997-02-01), None
patent: 757984 (1997-02-01), None
patent: 803505 (1997-10-01), None
patent: WO95/35275 (1995-12-01), None
patent: WO95/35276 (1995-12-01), None
patent: WO96/00214 (1996-01-01), None
patent: WO96/27583 (1996-09-01), None
patent: WO96/33172 (1996-10-01), None
patent: WO97/18194 (1997-05-01), None
patent: WO97/19068 (1997-05-01), None
patent: WO97/20824 (1997-06-01), None
patent: WO97/22587 (1997-06-01), None
patent: WO97/27174 (1997-07-01), None
patent: 97/45402 (1997-12-01), None
patent: WO98/03166 (1998-01-01), None
patent: WO98/07697 (1998-02-01), None
patent: WO98/08815 (1998-03-01), None
patent: WO98/08822 (1998-03-01), None
patent: WO98/08823 (1998-03-01), None
patent: WO98/08825 (1998-03-01), None
patent: WO98/08827 (1998-03-01), None
patent: WO98/08853 (1998-03-01), None
patent: WO98/16503 (1998-04-01), None
patent: WO98/16506 (1998-04-01), None
patent: WO98/16514 (1998-04-01), None
patent: WO98/16520 (1998-04-01), None
patent: WO98/27069 (1998-06-01), None
patent: WO98/31664 (1998-07-01), None
patent: WO98/33768 (1998-08-01), None
patent: WO98/34918 (1998-08-01), None
patent: WO98/39313 (1998-09-01), None
patent: WO98/39329 (1998-09-01), None
patent: WO98/42659 (1998-10-01), None
patent: WO98/43963 (1998-10-01), None
patent: WO 00/44730 (2000-08-01), None
Borkakoti, Matrix Metalloproteases: Variations on a Theme, Progress in Biophysics & Molecular Biology, 1998, vol. 70, No. 1, pp. 73-94.
Yu et al., Matrix Metalloproteases: Novel Targets for Directed Cancer Therapy, Drugs & Aging, Sep. 1997, vol. 11, No. 3, pp. 229-244.
International Search Report PCT/US02/34904 Mailed Mar. 04, 2003.
Black, D. K.; Landor, S. R.; Patel, A. N.; Whiter, P. F.J. Chem. Soc.(C) 1967, 2260-2262.
Campbell, R. W.; Hill, H. W.J. Org. Chem.1973, 38, 1047-1049.
Cowie, J. S.; Landor, P. D.; Landor, S. R. HJ. Chem. Soc.Perkin I 1973, 720-724.
Galantay, E.; Bacso, I.; Coombs, R. V.Synthesis1974, 344-346.
Keck, G. E.; Webb, R. R.Tetrahedron Lett.1982, 23, 3051-3054.
Asher, Vikram; Becu, Christian; Anteunis, Marc. J. O.; Callens, RolandTetrahedron Lett.1981, 22(2), 141-144.
Old, L.Science, 1985, 230, 630-632.
Lathbury, D.; Gallagher, T.J. Chem. Soc.Chem. Comm. 1986, 114-115.
Piguet, P.F.Grau, G. E.; et al.J. Exp. Med.1987, 166 1280-1289.
Kogami, Yuji; Okawa, Kenji,Bull. Chem. Soc. Jpn.1987, 60(8), 2963-2965.
Mathison, et al.J. Clin. Invest.1988, 81, 1925-1937.
Beutler, B.; Cerami, A.Ann. Rev. Biochem.1988, 57, 505-518.
Auvin, S.; Cochet, O.; Kucharczyk, N.; Le Goffic, F.; Badet, B.Bioorganic Chemistry, 1991, 19, 143-151.
T. W. Greene, P. G. M. Wuts “Protective Groups in Organic Synthesis”, 2ndEdition, 1991, Wiley & Sons, New York.
Miethke, et al.J. Exp. Med.1992, 175, 91-98.
Peterson, P. K.; Gekker, G. et al.J. Clin. Invest.1992, 89, 574-580.
Angle, S. R.; Breitenbucher, J. G.; Arnaiz, D.O. J. Org. Chem.1992, 57, 5947-5955.
Hotamisligil, G. S.; Shargill, N. S.; Spiegelman, B. M. et al.,Science1993, 259, 87-91.
Nigel RA Beeley; Phillip RJ Ansell; Andrew JP Docherty;Curr. Opin. Ther. Patents(1994) 4(1); 7-16.
Packer, M.Circulation, 1995, 92(6), 1379-1382.
Ferrari, R.; Bachetti, T. et al.Circulation, 1995, 92(6), 1479-1486.
Pallares-Trujillo, J.; Lopez-Soriano, F. J. Argiles,J. M. Med. Res. Reviews, 1995. 15(6), 533-546.
Rankin, E. C.; Choy, E. H.; Kassimos, D.; Kingsley, G. H.; Sopwith, A. M.; Isenberg, D. A.; Panayl, G. S. Br.J. Rheumatol, 1995, 34, 334-342.
J.R. Morphy; T.A. Millican; J.R. Porter;Curr. Medicinal. Chem.(1995) 2: 743-762.
John R. Porter, T. Andrew Millican; J. Richard Morphy; Recent Developments in Matrix Metalloproteinase Inhibitors;Exp. Opin. Ther. Patents, (1995) 5 (12): 1287-1296.
Peter Steele;Exp. Opin. Ther. Patents(1995) 5(2) 99-110.
Pharmaprojects, 1996 Therapeutic Updates 17 (Oct.) au197-M2Z.
Gerard M. McGreehan; Joanne Uhl;Current Pharmaceutical Design, 1996, 2, 662-667.
Recent Advances in Matrix Metalloproteinase Inhibitor Research, R. P. Beckett, A. H. Davidson, A. H. Drummon, P. Huxley and M. Whittaker,Drug Discovery Today, (Research Focus), vol. 1, 16-26 (1996).
Grossman, J. M.; Brahn,E. J. Women's Health1997, 6(6), 627-638.
Isomaki, P.; Punnonen,J. Ann. Med.1997, 29, 499-507.
MacPherson, et al. inJ. Med. Chem., 1997, 40, 2525-2532.
Shire, M.G.; Muller,G. W. Exp. Opin.Ther. Patents 1998, 8(5), 531-544.
Camussi, G., Lupia,E. Drugs, 1998, 55(5), 613-620.
Ksontini, R.; MacKay, S.L. D.; Moldawer, L. L.Arch. Surg.1998, 133, 558-567.
R Paul Beckett; Mark Whittaker;Exp. Opin. Ther. Patents(1998) 8(3); 259-281.
Scrip.1998, 2349, 20.
Tamura, et al. inJ. Med. Chem.1998, 41, 640-649.
Levin, J. I. ; DiJoseph, J. F.; Killar, L. M.; Sung, A.; Walter, T.; M. A.; Roth, C. E.; Skotnicki, J. R., Albright, J. D.Bioorg.&Med. Chem. Lett.1998, 8, 2657-2662.
Pikul, S.; McDow, Dunham, K. L.; Almstead, N. G.; De, B.; Natchus, . G.; Anastasio, M.V. McPhail, S. J.; Snider, C. E. ; Taiwo, Y. O.; Rydel, T.; Dunaway, C. M.; Gu, F., Mieling, G. E.J. Med. Chem.1998, 41, 3568-3571.
Clements, John M. et al., “Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor”, J. of Neuro. 74 (1997) 85-94.
Colon, A.L. et al., “Implication of TNF-α Convertase (TACE/ADAM17) in Inducible Nitric Oxide Synthase Expression and Inflammation in an Experimental Model and Colitis”, Cytokine, (2001), 16(6):220-226.
Duffy, Michael J. et al., “The ADAM's family of proteins: from basic studies to potential clinical applications”, Thromb Haemost (2003); 89:622-31.
Feldman, Arthur M. et al., “The Role of Tumor Necrosis Factor in the Pathophysiology of Heart Failure”, J. Am. Col. Cardio., 2000; 35(3):537-544.
Gilles, Stefanie et al., “Release of TNF-α during myocardial reperfusion depends on oxidative stress and its prevented by mast cell stabilizers”, Cardio. Research, 60 (2003) 608-616.
Hotamisligil, Gokhan S. et al., “Tumor Necrosis Factor-α: A Key Component of the Obesity-Diabetes Link”, Diab

Affiliated with

Also associated with

Rating

Allenic aryl sulfonamide hydroxamic acids as matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Allenic aryl sulfonamide hydroxamic acids as matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allenic aryl sulfonamide hydroxamic acids as matrix... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3864314